Evoke Pharma, Inc. filed its 10-K on Mar 21, 2023 for the period ending Dec 31, 2022. In this report its auditor, BDO LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.458 USD | +5.05% | -2.24% | -56.39% |
Apr. 24 | Transcript : Evoke Pharma, Inc. - Special Call | |
Mar. 21 | Evoke Pharma, Inc. Announces Board Changes as of March 31, 2024 | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.39% | 3.88M | |
+25.83% | 661B | |
+27.00% | 566B | |
-6.76% | 352B | |
+20.34% | 332B | |
+3.00% | 283B | |
+13.09% | 231B | |
+5.46% | 200B | |
-9.61% | 195B | |
-6.26% | 145B |
- Stock Market
- Equities
- EVOK Stock
- News Evoke Pharma, Inc.
- Evoke Pharma, Inc. Auditor Raises 'Going Concern' Doubt